Bibliografías temáticas / Yifeng tang / Artículos de revistas
Siga este enlace para ver otros tipos de publicaciones sobre el tema: Yifeng tang.

Artículos de revistas sobre el tema "Yifeng tang"

Autor: Grafiati
Publicado: 27 de julio de 2024
Última modificación: 31 de julio de 2025

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 19 mejores artículos de revistas para su investigación sobre el tema "Yifeng tang".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Han, Wu, Jie Liu, Yifan Luo, and Hongqu Tang. "No longer endemic to Africa: Kribiodosis Kieffer, 1921 (Diptera, Chironomidae) new to Oriental China with a phylogeny and expanded adult generic diagnoses." Zootaxa 5072, no. 6 (2021): 560–74. https://doi.org/10.11646/zootaxa.5072.6.4.

Texto completo
Resumen
Han, Wu, Liu, Jie, Luo, Yifan, Tang, Hongqu (2021): No longer endemic to Africa: Kribiodosis Kieffer, 1921 (Diptera, Chironomidae) new to Oriental China with a phylogeny and expanded adult generic diagnoses. Zootaxa 5072 (6): 560-574, DOI: 10.11646/zootaxa.5072.6.4
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Hamer, Matthew T., André Ibáñez Weemaels, Yifan Fu, et al. "New insights into the diversity and distribution of Leptanillinae (Formicidae) within China." Zootaxa 5471, no. 1 (2024): 99–112. https://doi.org/10.11646/zootaxa.5471.1.6.

Texto completo
Resumen
Hamer, Matthew T., Weemaels, André Ibáñez, Fu, Yifan, Xuan, Liu, Tse, Cheung Yau Leo, Tang, Kit Lam, Guénard, Benoit (2024): New insights into the diversity and distribution of Leptanillinae (Formicidae) within China. Zootaxa 5471 (1): 99-112, DOI: 10.11646/zootaxa.5471.1.6, URL: http://dx.doi.org/10.11646/zootaxa.5471.1.6
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Dong1, Yang, Shengchang Duan1, Qiuju Xia, et al. "Dual domestications and origin of traits in grapevine evolution." Science 379 (March 3, 2023): 892–901. https://doi.org/10.1126/science.add8655.

Texto completo
Resumen
Dong1, Yang, Duan1, Shengchang, Xia, Qiuju, Liang, Zhenchang, Dong1, Xiao, Margaryan, Kristine, Musayev, Mirza, Goryslavets, Svitlana, Zduni, Goran, Bert, Pierre-François, Lacombe11, Thierry, Maul1, Erika, Nick, Peter, Bitskinashvili, Kakha, Bisztray, György Dénes, Drori, Elyashiv, Lorenzis, Gabriella De, Cunha, Jorge, Popescu, Carmen Florentina, Arroyo-Garcia, Rosa, Arnold, Claire, Ergül, Ali, Zhu1, Yifan, Ma, Chao, Wang, Shufen, Liu1, Siqi, Tang, Liu, Wang, Chunping, Li, Dawei, Pan, Yunbing (2023): Dual domestications and origin of traits in grapevine evolution. Science 379: 892-901, DOI: 10
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Cortes-Cros, Marta, Henrik Moebitz, Stephanie Barbe, et al. "Abstract PR007: Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor with potent and selective anti-tumor activity in cancers with microsatellite instability." Molecular Cancer Therapeutics 22, no. 12_Supplement (2023): PR007. http://dx.doi.org/10.1158/1535-7163.targ-23-pr007.

Texto completo
Resumen
Abstract The RecQ DNA helicase WRN was identified as a synthetic lethal target in tumors with microsatellite instability (MSI) by several genetic screens. Despite recent advances in the treatment of MSI tumors by immune checkpoint inhibitors, a significant proportion of patients still fails to respond to or relapses after single agent anti-PD1 or combination of anti-PD1 plus anti-CTLA4 treatments. We present the biochemical, cellular and pharmacological characterization of the first potent and selective WRN helicase inhibitor, HRO761. We show that HRO761 is an allosteric WRN inhibitor that bin
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Zhou, Yifan, Yusra B. Medik, Bhakti Patel, et al. "Abstract 5545: Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration." Cancer Research 82, no. 12_Supplement (2022): 5545. http://dx.doi.org/10.1158/1538-7445.am2022-5545.

Texto completo
Resumen
Abstract Immunotherapies such as anti-CTLA-4 immune checkpoint blockade (ICB) have revolutionized cancer treatment, yet quality of life and continuation of therapy can be constrained by off-target tissue damage or immune-related adverse events (irAEs). At present, there is limited understanding of irAE mechanisms, hampering development of approaches to mitigate their damage. We addressed this problem by generating animal models of intestinal irAE. Our results show that disruption of homeostatic immunity by genetic predisposition to intestinal inflammation or acute gastrointestinal infection se
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Yang, Cuiqing, Yifang Wang, Tingting Liu, et al. "Abstract 2899: Small molecule inhibitor of ubiquitin ligase CBL-B enhanced anti-tumor response of CAR-T and CAR-NK cell therapies." Cancer Research 83, no. 7_Supplement (2023): 2899. http://dx.doi.org/10.1158/1538-7445.am2023-2899.

Texto completo
Resumen
Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy is an emerging therapeutic option for cancer treatment. However, its efficacy is limited, especially in solid tumors. This is partly because the CAR T cells become dysfunctional and exhausted in the tumor microenvironment. However, the key pathways responsible for impaired function of exhausted T cells remain unclear. Immunosuppressive cytokines or checkpoint proteins like TGF-β and PD-L1, are overproduced, which may lead to the downregulation of CD8+ T cell action and the promotion of T-reg maturation. E3 ligase Casitas B-L
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Wang, Xiaobin Summer, Sining Zhu, Haili Ding, et al. "Abstract 360: Discovery of selective and orally bioavailable PKMYT1 inhibitor: characterization of anti-tumor activities as single and dual agents." Cancer Research 85, no. 8_Supplement_1 (2025): 360. https://doi.org/10.1158/1538-7445.am2025-360.

Texto completo
Resumen
Abstract Advancing effective cancer therapies requires innovative approaches to better understand complex biological interactions. PKMYT1, a crucial regulator of the cell cycle involved in the G2/M transition through inhibitory phosphorylation of CDK1, has emerged as a promising therapeutic target. Inactivation of PKMYT1 is synthetically lethal in tumor cells with genomic alterations leading to high replication stress, such as CCNE1 amplification, which is frequently found in high-grade serous ovarian, uterine, and gastro-esophageal cancers. In this report, we present a series of potent PKMYT1
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Yang, Cuiqing, Fuwei Jiang, Yifang Wang, et al. "Abstract 2900: To develop a next generation NK therapy with deep and durable response by engineered CD16 enhancing NK cytotoxicity." Cancer Research 83, no. 7_Supplement (2023): 2900. http://dx.doi.org/10.1158/1538-7445.am2023-2900.

Texto completo
Resumen
Abstract Introduction: Allogeneic NK cell-based therapies have been demonstrated to elicit clinical efficacy against hematopoietic malignancies. Unlike T-cell therapies, allogeneic NK cells do not cause toxicities such as serious cytokine release syndrome, neurotoxicity, or graft-vs-host-disease, and are less expensive. We believe NK cell-based therapies provide an important platform for “off-shelf” allogeneic cell therapies, so we designed a panel of arming strategies to enhance NK cytotoxicity and elicit deep and durable response. CD16a is a transmembrane protein that co-localizes with CD3ζ
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Yang, Cuiqing, Fuwei Jiang, Yifang Wang, et al. "Abstract 4087: Co-expression of membrane bound IL-15 enhanced anti-tumor response of CAR-T." Cancer Research 83, no. 7_Supplement (2023): 4087. http://dx.doi.org/10.1158/1538-7445.am2023-4087.

Texto completo
Resumen
Abstract Introduction: Chimeric antigen receptors (CARs) T cells have been used successfully to treat patients with hematologic malignancies, but showed less effective in solid tumors. We investigated multiple approaches to engineer and enhance CAR-T activity in solid tumors. It has been previously reported that improvement in the quality of CAR-T cells, through CAR design or manufacturing optimization, could enhance the therapeutic potential of CAR-T cells. One parameter influencing the effectiveness of CAR-T cell therapy is the differentiation status of the final product: CAR-T cells that ar
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Yang, Cuiqing, Yifang Wang, Tingting Liu, et al. "Abstract 4078: Optimized chimeric antigen receptors (CARs) for CAR-NK cell therapies." Cancer Research 83, no. 7_Supplement (2023): 4078. http://dx.doi.org/10.1158/1538-7445.am2023-4078.

Texto completo
Resumen
Abstract Introduction: CAR-T-cell therapy has shown great success in treating hematopoietic malignancies. Allogenic NK cell-based therapies have also been shown to mount potent responses against hematopoietic malignancies. Unlike T-cell therapies, allogeneic NK cells do not cause toxicities such as serious cytokine release syndrome, neurotoxicity, or graft-vs-host-disease. Several groups have demonstrated the clinical efficacy of allogeneic CAR-expressing NK cells that utilize CARs developed for T-cells. However, activating receptor signaling in NK cells is different from T cells. NK cell-medi
Los estilos APA, Harvard, Vancouver, ISO, etc.
11

Yang, Cuiqing, Yifang Wang, Tingting Liu, et al. "Abstract 4077: Dual-targeted CAR-NK cell therapy: optimized CAR design to prevent antigen escape and elicit a deep and durable response in multiple myeloma." Cancer Research 83, no. 7_Supplement (2023): 4077. http://dx.doi.org/10.1158/1538-7445.am2023-4077.

Texto completo
Resumen
Abstract Introduction: Multiple myeloma (MM) is an incurable hematologic malignancy and new strategies that offer a chance of obtaining long-term progression free survival are urgently needed. MM is associated with profound immune alterations and dysfunction of natural killer (NK) cells have been demonstrated to be crucial factors in MM progression. Myeloma cells are susceptible to killing by natural killer (NK) cells but acquire the ability to elude NK cell surveillance by avoiding recognition and suppressing NK cell function. Given the role of NK cells in the pathogenesis of MM, interest in
Los estilos APA, Harvard, Vancouver, ISO, etc.
12

Ouyang, Jie, Yifen Wu, Pengfei Qian, et al. "Abstract P2-12-22: A multicenter, single-arm, phase II clinical trial of oral CDK4/6 inhibitor darciclib in combination with endocrine therapy in adjuvant treatment for hormone receptor-positive, HER2-negative female breast cancer." Clinical Cancer Research 31, no. 12_Supplement (2025): P2–12–22—P2–12–22. https://doi.org/10.1158/1557-3265.sabcs24-p2-12-22.

Texto completo
Resumen
Abstract Background: Although the role of endocrine therapy in the adjuvant treatment of HR+/HER2- breast cancer has been established, Early HR positive and HER2 negative breast cancer show a long-term risk of recurrence. Studies have shown that about 20% of patients experience recurrence and metastasis after receiving adjuvant endocrine therapy for 5 years. CDK4/6 inhibitor combined with endocrine therapy for HR+/HER2- breast cancer has been proven to have synergistic effects. Previous studies have shown that Abemaciclib and ribociclib can reduce the risk of recurrence and increase iDFS in ea
Los estilos APA, Harvard, Vancouver, ISO, etc.
13

Tang, Qiuqiong, Douglas D. Fang, Huidan Yu, et al. "Abstract 2998: Inhibition of MDM2-p53 interaction by alrizomadlin (APG-115) induces pyroptotic cell death in gasdermin E (GSDME)-expressing cancer cells." Cancer Research 82, no. 12_Supplement (2022): 2998. http://dx.doi.org/10.1158/1538-7445.am2022-2998.

Texto completo
Resumen
Abstract Mouse double minute-2 (MDM2)-p53 inhibitor alrizomadlin (APG-115) is an investigational agent known to induce apoptosis of TP53-wild type cancer cells (Aguilar et al, J Med Chem 2017). Emerging evidence suggests that activation of p53 by alrizomadlin also promotes antitumor immunity in the tumor microenvironment (Fang et al, JITC 2019; Zhou et al, Nat Immunol 2021), but the links between these processes are incompletely understood. Pyroptosis refers to inflammatory programmed cell death. Central to this process is the family of gasdermins, which can form pores in cell plasma membranes
Los estilos APA, Harvard, Vancouver, ISO, etc.
14

Wang, Guangfeng, Eric Liang, Chunyang Tang, et al. "Abstract 5439: MDM2 inhibitor alrizomadlin (APG-115) stabilizes p53 and synergizes with proteasome inhibitors in multiple myeloma." Cancer Research 82, no. 12_Supplement (2022): 5439. http://dx.doi.org/10.1158/1538-7445.am2022-5439.

Texto completo
Resumen
Abstract Multiple myeloma (MM) accounts for about 2% of all cancers and 18% of all hematologic malignancies in the US. Newly developed treatments (e.g., immunomodulators, proteasome inhibitors, monoclonal antibodies) have significantly improved outcomes, but MM inevitably relapses and is considered incurable. Genomic analysis shows that the TP53 gene encoding tumor suppressor protein p53 is infrequently mutated in patients with MM, of whom about 82% retain wild-type (WT) TP53. Mouse double minute 2 (MDM2) is an E3 ubiquitin ligase that inhibits p53 via proteasome degradation. Proteasome inhibi
Los estilos APA, Harvard, Vancouver, ISO, etc.
15

Deng, Jing, Kaixiang Zhang, Qiuqiong Tang, et al. "Abstract 3964: Co-targeting MDM2-p53 and BCL-2 apoptosis pathways overcomes resistance conferred by acquired BCL-2 gene mutations in preclinical models." Cancer Research 82, no. 12_Supplement (2022): 3964. http://dx.doi.org/10.1158/1538-7445.am2022-3964.

Texto completo
Resumen
Abstract The BCL-2 inhibitor venetoclax has shown impressive efficacy in patients with chronic lymphocytic leukemia, but its clinical benefits are limited by acquired BCL-2 gene mutations that confer drug resistance. Among acquired mutations, those proximal to BH3 binding motifs (e.g., G101V, D103E, and V156D) have the most significant impact on BCL-2 binding to BH3-only prodeath proteins and BH3 mimetics (e.g., venetoclax). Hence, it is important to identify novel therapeutics that address this emerging unmet need. To this end, we investigated the effect of co-targeting BCL-2 and MDM2-p53 apo
Los estilos APA, Harvard, Vancouver, ISO, etc.
16

Cao, Guoshuai, Yifei Hu, Tony Pan, et al. "Abstract 6399: Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma." Cancer Research 85, no. 8_Supplement_1 (2025): 6399. https://doi.org/10.1158/1538-7445.am2025-6399.

Texto completo
Resumen
Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy has expanded therapeutic options for patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). However, progress in improving clinical outcomes has been limited by an incomplete understanding of CAR T-cell differentiation in patients. Methods: To comprehensively investigate CAR T-cell differentiation in vivo, we performed single-cell, multi-modal, and longitudinal analyses of CD28-costimulated CAR T cells from infusion product and peripheral blood (day 8-28) of seven patients with r/r DLBCL who exhibited a c
Los estilos APA, Harvard, Vancouver, ISO, etc.
17

卓, 清芬. "自我呈現與他人形塑———湯貽汾《吟釵圖》詩卷題詠析論". 人文中國學報, 1 червня 2018, 97–144. http://dx.doi.org/10.24112/sinohumanitas.262065.

Texto completo
Resumen
LANGUAGE NOTE | Document text in Chinese; abstract also in English.
 清代詩畫家湯貽汾（1778—1853）爲記憶親情、感念母德，繪製《吟釵圖》，録母親楊氏（1752—1812）《斷釵吟》七絕二首於其上，遍徵題詠。是時和詩與題畫者甚衆，爲道光、咸豐之間的一大盛事，後輯成《斷釵吟》四卷出版。
 本文從楊氏《斷釵吟》口占二首與湯貽汾之和詩談起，説明《斷釵吟》徵詩活動與《吟釵圖》的産生，並整理《斷釵吟》的題詠社群。題詠者多從湯貽汾的人際關係延伸而來，而閨秀的家族題詠亦爲一大特色。從楊氏《斷釵吟》的自述，可以了解清代女性的自我觀看和自我呈現的側重點，另由他人題詠作品的切入角度，可以觀察題詠者對《吟釵圖》的觀看視角和性别形塑。
 《吟釵圖》的詩卷題詠，不僅肯定了女性“才”、“德”並立的典範意義，也彰顯了忠義節孝的價值觀，在當時具有一定的影響力。
 The poet and painter of the Qing Dynasty, Tang Yifen (1778-1853), created a painting entitled “Eulogy on a Hairpin” as commemoration and gratitude for his mother. He inscri
Los estilos APA, Harvard, Vancouver, ISO, etc.
18

柯, 秉芳. "世變、歷史與記憶———湯貽汾《如此江山圖》與鴉片戰争時期詩詞中的鎮江之戰". 人文中國學報, 1 липня 2023, 73–107. http://dx.doi.org/10.24112/sinohumanitas.362703.

Texto completo
Resumen
LANGUAGE NOTE | Document text in Chinese; abstract also in English.
 道光二十二年（1842），英軍發動揚子江戰役，攻陷鎮江，隨後直抵江寧，迫使清廷簽下不平等的《南京條約》。戰前，黄爵滋以嚴禁鴉片名重當時；戰後，黄爵滋以失察銀庫遭到彈劾。名畫家湯貽汾爲其作《如此江山圖》，描繪戰後焦山風景，陳方海題記拈出圖中隱寄“風景不殊”的感慨，或與鎮江之戰有著緊密的關聯。本文以《如此江山圖》爲開展，試圖透過圖畫題詠及當代時人詩詞中對鎮江之戰的描寫，探究士人如何憑藉圖畫、詩、詞的不同特質，互文參照，形成共同的歷史記憶。除了從題詠中探掘圖畫的創作旨趣，亦從中發掘題詠者有意識地自圖畫延伸出的畫外之意；在“詩史”義理精神的闡發下，建構對陳化成以及兩江總督牛鑑、副督統海齡的褒貶形象；並藉由抒寫鎮江興亡與效仿蘇、辛體的詞作，管窺詞體創作中對“京口三山”一脈相承的書寫傳統。
 In the 22nd year of the Daoguang reign (1842), the British Armed Forces waged the Battle of Yangzi River, captured Zhenjiang, and reached Jiangning, compelling the Qing court t
Los estilos APA, Harvard, Vancouver, ISO, etc.
19

"2023 Beijing Health Data Science Summit." Health Data Science 4 (January 2024). http://dx.doi.org/10.34133/hds.0112.

Texto completo
Resumen
The 5th annual Beijing Health Data Science Summit, organized by the National Institute of Health Data Science at Peking University, recently concluded with resounding success. This year, the summit aimed to foster collaboration among researchers, practitioners, and stakeholders in the field of health data science to advance the use of data for better health outcomes. One significant highlight of this year’s summit was the introduction of the Abstract Competition, organized by Health Data Science , a Science Partner Journal, which focused on the use of cutting-edge data science methodologies, p
Los estilos APA, Harvard, Vancouver, ISO, etc.
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía